Cartesian Therapeutics (RNAC) Institutional Ownership $17.02 -0.10 (-0.58%) (As of 11/14/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Cartesian Therapeutics (NASDAQ:RNAC)CurrentInstitutional OwnershipPercentage86.95%Number ofInstitutional Buyers(last 12 months)15TotalInstitutional Inflows(last 12 months)$366.79MNumber ofInstitutional Sellers(last 12 months)5TotalInstitutional Outflows(last 12 months)$27.44M Get RNAC Insider Trade Alerts Want to know when executives and insiders are buying or selling Cartesian Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data RNAC Institutional Buying and Selling by Quarter Ad Porter & CompanyThe next assassination attempt won’t be on TrumpPresident Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you watched the President’s 25-minute victory speech, you probably noticed he spent nearly four minutes speaking about one very controversial person.I share with you in this special investigative documentary. Cartesian Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/13/2024 Great Point Partners LLC200,000$3.22M0.9%N/A0.787% 11/13/2024 BNP Paribas Financial Markets1,651$27K0.0%+122.5%0.006% 11/13/2024 FMR LLC2,851,830$45.97M0.0%+458.3%11.219% 10/23/2024 Lake Street Advisors Group LLC15,822$255K0.0%-50.0%0.074% 9/16/2024Point72 DIFC Ltd1,725$47K0.0%N/A0.008% 9/16/2024Cubist Systematic Strategies LLC13,010$351K0.0%N/A0.061% Get the Latest News and Ratings for RNAC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cartesian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 9/16/2024Point72 Asia Singapore Pte. Ltd.1,824$49K0.0%N/A0.009% 8/27/2024Logos Global Management LP90,000$2.43M0.2%N/A0.506% 8/15/2024Point72 Asia Singapore Pte. Ltd.1,824$49K0.0%N/A0.009% 8/14/2024Cubist Systematic Strategies LLC13,010$351K0.0%N/A0.061% 8/14/2024Point72 DIFC Ltd1,725$47K0.0%N/A0.008% 8/14/2024Marshall Wace LLP30,038$811K0.0%N/A0.140% 8/14/2024Logos Global Management LP90,000$2.43M0.2%N/A0.421% 8/9/2024 Renaissance Technologies LLC17,052$461K0.0%-96.9%0.096% 8/6/2024 Lake Street Advisors Group LLC31,644$855K0.0%N/A0.178% 8/1/2024 Rhumbline Advisers8,487$229K0.0%-93.5%0.048% 7/26/2024 Bank of New York Mellon Corp19,916$538K0.0%-93.7%0.112% 7/22/2024 Hall Laurie J Trustee1,759$48K0.0%-96.7%0.010% 5/17/2024 Artal Group S.A.9,136,635$5.94M0.2%N/A171.098% 5/14/2024 American International Group Inc.56,202$37K0.0%N/A1.052% 5/10/2024 Vanguard Group Inc.6,315,113$4.11M0.0%N/A118.172% 5/7/2024 SG Americas Securities LLC47,134$31K0.0%N/A0.883% 5/3/2024Delphi Financial Group Inc.660,852$430K0.3%N/A12.261% 5/1/2024 BNP Paribas Financial Markets59,125$38K0.0%N/A1.097% 4/23/2024 Hall Laurie J Trustee52,775$34K0.0%N/A0.979% (Data available from 1/1/2016 forward) RNAC Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of RNAC shares? During the previous two years, 18 institutional investors and hedge funds held shares of Cartesian Therapeutics. The most heavily invested institutionals were FMR LLC ($45.97M), Artal Group S.A. ($5.94M), Vanguard Group Inc. ($4.11M), Great Point Partners LLC ($3.22M), Logos Global Management LP ($2.43M), Marshall Wace LLP ($811K), and Bank of New York Mellon Corp ($538K).Learn more on RNAC's institutional investors. What percentage of Cartesian Therapeutics stock is owned by institutional investors? 86.95% of Cartesian Therapeutics stock is owned by institutional investors. Learn more on RNAC's institutional investor holdings. Which institutional investors have been buying Cartesian Therapeutics stock? Of the 15 institutional investors that purchased Cartesian Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Artal Group S.A. ($9.14M), Vanguard Group Inc. ($6.32M), FMR LLC ($2.34M), Delphi Financial Group Inc. ($660.85K), Great Point Partners LLC ($200K), Logos Global Management LP ($180K), and BNP Paribas Financial Markets ($60.03K). How much institutional buying is happening at Cartesian Therapeutics? Institutional investors have bought a total of 19,144,599 shares in the last 24 months. This purchase volume represents approximately $366.79M in transactions. Which Cartesian Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Cartesian Therapeutics stock in the last 24 months: Renaissance Technologies LLC ($536.55K), Bank of New York Mellon Corp ($297.41K), Rhumbline Advisers ($121.40K), Hall Laurie J Trustee ($51.02K), and Lake Street Advisors Group LLC ($15.82K). How much institutional selling is happening at Cartesian Therapeutics? Institutional investors have sold a total of 1,022,188 shares in the last 24 months. This volume of shares sold represents approximately $27.44M in transactions. Related Companies IMCR Institutional Ownership OCUL Institutional Ownership KNSA Institutional Ownership DAWN Institutional Ownership SPRY Institutional Ownership XNCR Institutional Ownership RCUS Institutional Ownership NTLA Institutional Ownership RCKT Institutional Ownership TVTX Institutional Ownership This page (NASDAQ:RNAC) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredElon Musk has put himself in their crosshairsToday, I have another controversial prediction. One which I will take no pleasure in seeing come true. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
